These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35656996)

  • 41. Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis.
    Del Giovane C; Boncoraglio GB; Bertù L; Banzi R; Tramacere I
    BMC Neurol; 2021 Aug; 21(1):319. PubMed ID: 34399713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
    Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
    Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative efficacy and safety of multiple antiplatelet therapies for secondary prevention of ischemic stroke or transient ischemic attack: A network meta-analysis.
    Xiang RW; Han RB; Yang JY; Zhao MY; Zhao QC; Chen HS; Zhao FQ; Sun ZY; Zhao T; Song TY
    J Neurol Sci; 2019 Apr; 399():199-206. PubMed ID: 30849580
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
    Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
    Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual Therapy with Aspirin and Cilostazol May Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study.
    Ohnuki Y; Ohnuki Y; Kohara S; Shimizu M; Takizawa S
    Intern Med; 2017; 56(11):1307-1313. PubMed ID: 28566591
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
    Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
    Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cilostazol versus Aspirin or Clopidogrel for Reducing Post-Stroke Aspiration Pneumonia: A Nationwide Retrospective Cohort Study.
    Sato S; Yamana H; Kumazawa R; Watanabe H; Fujita A; Matsui H; Fushimi K; Yasunaga H
    Cerebrovasc Dis; 2024; 53(2):152-159. PubMed ID: 37586338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cilostazol for Secondary Stroke Prevention: History, Evidence, Limitations, and Possibilities.
    de Havenon A; Sheth KN; Madsen TE; Johnston KC; Turan TN; Toyoda K; Elm JJ; Wardlaw JM; Johnston SC; Williams OA; Shoamanesh A; Lansberg MG
    Stroke; 2021 Oct; 52(10):e635-e645. PubMed ID: 34517768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.
    Takabayashi N; Murata K; Tanaka S; Kawakami K
    Pharmacoeconomics; 2015 Oct; 33(10):1091-100. PubMed ID: 25995130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
    Matchar DB; Samsa GP; Liu S
    Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiplatelet Use in Ischemic Stroke.
    Kamarova M; Baig S; Patel H; Monks K; Wasay M; Ali A; Redgrave J; Majid A; Bell SM
    Ann Pharmacother; 2022 Oct; 56(10):1159-1173. PubMed ID: 35094598
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction.
    Inoue T; Kobayashi M; Uetsuka Y; Uchiyama S
    Circ J; 2006 Apr; 70(4):453-8. PubMed ID: 16565564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.
    Heeg BM; Peters RJ; Botteman M; van Hout BA
    Pharmacoeconomics; 2007; 25(9):769-82. PubMed ID: 17803335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Navigating Antiplatelet Treatment Options for Stroke: Evidence-Based and Pragmatic Strategies.
    Moustafa B; Testai FD
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):789-802. PubMed ID: 36227497
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Wu B; Kun L; Liu X; He B
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI Trial.
    Lee CH; Lee JY; Park GM; Lee SW; Kim HS; Choi YJ; Nam CW; Cho JH; Shin WY; Seo JB; Choi SW; Lee JH; Min PK; Her SH; Lee PH; Ahn JM; Park DW; Kang SJ; Kim YH; Lee CW; Park SW; Park SJ
    Am J Cardiol; 2018 Feb; 121(4):423-429. PubMed ID: 29273207
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
    Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T
    Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.